CANC - ETF AI Analysis
Top Page
Tema Oncology ETF (CANC)
Rating:60Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and in the most recent month, indicating positive momentum in its oncology-focused strategy.
Leading Holdings With Solid Results
Several of the largest positions, including Revolution Medicines, Immunome, and Bristol-Myers Squibb, have delivered strong year-to-date performance that supports the fund’s returns.
Focused Exposure to Health Care
With most assets in health care and oncology-related companies, the ETF offers targeted exposure to a specialized area that may benefit from medical innovation.
Negative Factors
High Sector Concentration
The fund is heavily concentrated in health care, which increases the risk that a downturn or regulatory change in this single sector could significantly hurt performance.
Limited Geographic Diversification
With the vast majority of holdings in U.S. companies, the ETF offers little geographic diversification and is highly tied to the U.S. market and policy environment.
Relatively High Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which means more of the returns are used to cover fees instead of staying with investors.
CANC vs. SPDR S&P 500 ETF (SPY)
AUM175.47M
RegionGlobal
Expense Ratio0.75%
Beta0.82
IssuerTema
Inception DateAug 15, 2023
Dividend Yield0.05%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume26,946
30 Day Avg. Volume24,375
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
53.59Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering57
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CANC Summary
The Tema Oncology ETF (CANC) is a health care fund focused specifically on cancer-related companies, mainly in the pharma, biotech, and life sciences areas. It does not track a traditional index, but instead selects firms working on cancer drugs and treatments. Well-known holdings include AstraZeneca and Eli Lilly, along with several smaller biotech names. Someone might invest in this ETF to tap into the long-term growth potential of new cancer therapies while spreading their money across many companies instead of picking just one. A key risk is that biotech and drug stocks can be very volatile and may rise or fall sharply.
How much will it cost me?The Tema Oncology ETF has an expense ratio of 0.75%, which means you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on a specialized niche in the health care sector that requires expert research and selection of companies.
What would affect this ETF?The Tema Oncology ETF could benefit from advancements in cancer research and increased global demand for innovative treatments, as well as strong performance from top holdings like Eli Lilly and Roche, which are leaders in oncology. However, it may face challenges from regulatory hurdles, high development costs in the biotech sector, and potential economic downturns that could impact funding for healthcare innovation.
CANC Top 10 Holdings
This oncology-focused ETF is essentially a cancer-care battleground, with a few high-flyers doing the heavy lifting while some smaller biotechs weigh it down. Revolution Medicines and Celcuity have been rising sharply, giving the fund a shot of momentum, while big pharma names like Eli Lilly, Merck, and Novartis provide a steadier backbone and help smooth the ride. On the flip side, Cogent Biosciences and Immunome have been lagging, acting like sandbags on performance. The portfolio is almost entirely health care and globally diversified, mixing U.S. innovators with European pharma giants.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Revolution Medicines | 6.59% | $11.57M | $31.73B | 263.18% | 52 Neutral | |
| Eli Lilly & Co | 5.29% | $9.29M | $1.07T | 48.52% | 72 Outperform | |
| Legend Biotech | 4.49% | $7.87M | $6.06B | -6.80% | 46 Neutral | |
| Novartis AG | 4.28% | $7.51M | CHF215.38B | 21.53% | 80 Outperform | |
| Roche Holding | 4.25% | $7.46M | $327.08B | 25.99% | 74 Outperform | |
| Cogent Biosciences | 4.23% | $7.43M | $5.30B | 349.56% | 37 Underperform | |
| Merck & Company | 3.71% | $6.51M | $298.33B | 52.96% | 80 Outperform | |
| Immunome | 3.62% | $6.35M | $2.10B | 103.50% | 63 Neutral | |
| Bristol-Myers Squibb | 3.55% | $6.23M | $116.95B | 13.41% | 78 Outperform | |
| AstraZeneca | 3.29% | $5.78M | $286.97B | 28.53% | 80 Outperform |
CANC Technical Analysis
Negative
―
Price Trends
37.61
Negative
37.09
Negative
34.21
Positive
Market Momentum
-0.28
Positive
39.52
Neutral
20.13
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CANC, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 37.39, equal to the 50-day MA of 37.61, and equal to the 200-day MA of 34.21, indicating a neutral trend. The MACD of -0.28 indicates Positive momentum. The RSI at 39.52 is Neutral, neither overbought nor oversold. The STOCH value of 20.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CANC.
CANC Peer Comparison
Comparison Results
Performance Comparison
CANC
Tema Oncology ETF
36.12
10.16
39.14%
MGNR
American Beacon GLG Natural Resources ETF
―
―
―
AVRE
Avantis Real Estate ETF
―
―
―
VOLT
Tema Electrification ETF
―
―
―
EIPX
FT Energy Income Partners Strategy ETF
―
―
―
VGSR
Vert Global Sustainable Real Estate ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents